Literature DB >> 20385571

Analysis of pharmacodynamic interaction of sevoflurane and propofol on Bispectral Index during general anaesthesia using a response surface model.

J C Diz1, R Del Río, A Lamas, M Mendoza, M Durán, L M Ferreira.   

Abstract

BACKGROUND: Propofol and sevoflurane act on the GABA(A) receptor, modulating the function of this receptor in an additive manner. The pharmacodynamic interaction of both drugs considering their effect on EEG activity analysed by the bispectral index (BIS) was identified as additive, but this has not been studied in a clinical setting. The objective of this study was to analyse the pharmacodynamic interaction of propofol and sevoflurane on BIS using a surface response model in patients undergoing general anaesthesia with i.v. induction and inhalation maintenance.
METHODS: We performed a prospective study in 24 patients undergoing general anaesthesia with propofol induction and sevoflurane maintenance. Anaesthetic depth was measured with a BIS VISTA Bilateral monitor. Propofol biophase concentration was determined using a three-compartment pharmacokinetic model, and sevoflurane end-tidal concentration was measured continuously. The response surface model described by Minto and colleagues was used to analyse the interaction. Statistical analysis was performed with Excel 2002 and SPSS v11.0.
RESULTS: The mean value of U(50)(theta) was 0.956 (sd 0.029) in the overall estimated data, and remained within the predefined range for all ratios of the drugs, fulfilling the criterion of additivity. The median of the weighted residuals between the actual BIS value and the BIS value predicted by the model was -5.926%.
CONCLUSIONS: Under the study conditions, it was confirmed that sevoflurane and propofol have an additive effect on BIS, with no evidence suggesting the existence of a synergistic effect for the concentrations of both drugs typically used in clinical practice.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20385571     DOI: 10.1093/bja/aeq081

Source DB:  PubMed          Journal:  Br J Anaesth        ISSN: 0007-0912            Impact factor:   9.166


  7 in total

Review 1.  Pharmacokinetic-pharmacodynamic modelling in anaesthesia.

Authors:  Pedro L Gambús; Iñaki F Trocóniz
Journal:  Br J Clin Pharmacol       Date:  2015-01       Impact factor: 4.335

2.  Sevoflurane/propofol coadministration provides better recovery than sevoflurane in combined general/epidural anesthesia: a randomized clinical trial.

Authors:  Chao Liang; Ming Ding; Fang Du; Jing Cang; Zhanggang Xue
Journal:  J Anesth       Date:  2014-02-21       Impact factor: 2.078

Review 3.  Anaesthetic interventions for prevention of awareness during surgery.

Authors:  Anthony G Messina; Michael Wang; Marshall J Ward; Chase C Wilker; Brett B Smith; Daniel P Vezina; Nathan Leon Pace
Journal:  Cochrane Database Syst Rev       Date:  2016-10-18

4.  Synergism between rocuronium and cisatracurium: comparison of the Minto and Greco interaction models.

Authors:  Soeun Jeon; Jae Young Kwon; Hae-Kyu Kim; Tae Kyun Kim
Journal:  Korean J Anesthesiol       Date:  2016-06-22

5.  Incidence of postoperative nausea and vomiting is not increased by combination of low concentration sevoflurane and propofol compared with propofol alone in patients undergoing laparoscopic gynecological surgery.

Authors:  Yuka Uchinami; Satoshi Takikawa; Fumiki Takashima; Yosuke Maeda; Satoki Nasu; Ayumi Ito; Tatushi Saito
Journal:  JA Clin Rep       Date:  2019-11-02

6.  A Co-Induction Technique Utilizing 4% Sevoflurane Followed by 0.75 mg/kg Propofol in Elderly Patients Undergoing Minimally Invasive Procedures: A Prospective Randomized Control Study.

Authors:  Omar A Ababneh; Aiman M Suleiman; Isam K Bsisu; Subhi M Al-Ghanem; Walid K Samarah; Khaled R Al-Zaben; Ibraheem Y Qudaisat; Lubna A Khreesha; Ghazi M Al Edwan; Mujalli M Murshidi
Journal:  Medicina (Kaunas)       Date:  2020-12-10       Impact factor: 2.430

Review 7.  Clinical Pharmacokinetics and Pharmacodynamics of Propofol.

Authors:  Marko M Sahinovic; Michel M R F Struys; Anthony R Absalom
Journal:  Clin Pharmacokinet       Date:  2018-12       Impact factor: 6.447

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.